Q-omics provides the consensus-scored BAIAP2 profile across patient tissues and cancer cell-line models. BAIAP2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, BAIAP2 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, BAIAP2 protein abundance shows 23,165 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, COAD, and GBM as cancer lineages where BAIAP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BAIAP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BAIAP2 survival associations across molecular data types. BAIAP2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BAIAP2 RNA expression–survival associations across cancer types. High BAIAP2 expression shows unfavorable associations in BLCA, ACC, UCS, LGG and SKCM, but favorable associations in CESC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for BAIAP2 RNA expression.
This table summarizes BAIAP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BAIAP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BAIAP2 shows lower tumor expression in KICH, KIRC and LUSC and higher tumor expression in COAD, THCA and BRCA. The COAD box plot shows higher BAIAP2 RNA expression in tumor versus normal tissue (log2 FC = +1.009, t-test p < 0.001).
This table shows molecular features associated with BAIAP2 in patient tissues and cancer cell lines. In patient samples, BAIAP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, BAIAP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
